DelveInsight’s ‘Gout Pipeline Insights’ report offers comprehensive coverage of the emerging Gout therapeutics landscape in different stages of development from pre-clinical till a late-end stage, along with dormant, inactive, and abandoned drugs agents. 

The Gout Pipeline report provides a holistic picture of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space, and growth prospects across the Gout domain.

Around 40+ key companies are developing therapies for Gout. Selecta Biosciences appears to have the upper leg being the only company with its Gout drug candidate in the most advanced stage (Phase III).

 

Some of the key highlights from the Gout Pipeline report:

• The Gout Pipeline report offers a rich analysis of 40+ key players and 40+ key therapies.
• Gout pipeline comprises therapies in different stages of the clinical phase such as include PRX-115, SAP-001, HZN-003, URC-102, SHR4640, NC-2700, XNW3009, LC350189, SEL-212, AC-201, Dapansutrile, HP501, DYV700, D-0120,  ARO-XDH, WT-2107, ACQT1127, TJC0434, ABP-072, and others, with many others expected to enter the Gout market in the next decade. 
• Some of the key companies engaged in strengthening the Gout Pipeline are Protalix BioTherapeutics, Shanton Pharma, Horizon Therapeutics, JW Pharmaceutical, Jiangsu Hengrui Medicine Co., Nippon Chemiphar, Sinovent, LG Chem, Selecta Biosciences, TWi Biotechnology, Olatec Therapeutics,  Hinova pharmaceuticals, Dyve Biosciences, InventisBio, Arrowhead Pharmaceuticals, Wellstat Therapeutics Corporation, Acquist Therapeutics, TaiwanJ Pharmaceuticals, Atom Bioscience among others
• In June 2020, Swedish Orphan Biovitrum AB and Selecta Biosciences, Inc. announced that the companies have entered into a strategic licensing agreement for the product candidate SEL-212. SEL-212 is a combination of Selecta’s tolerogenic ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase) that is designed to durably control serum uric acid, reduce immunogenicity, and allow for repeated monthly dosing for the treatment of chronic refractory gout. This agreement represents an important milestone for Selecta, and for patients with chronic refractory gout, as Sobi is the ideal partner with the commitment, resources, and complementary product portfolio to advance SEL-212 through development and commercialization.
• In May 2021, Fortress Biotech announced that it had entered into an exclusive licensing agreement with Fuji Yakuhin Co. Ltd. to develop Dotinurad in the United States, United Kingdom, European Union and Canada. Under the terms of the agreement, the Company acquired exclusive development and marketing rights in North America and Europe from Fuji. Fuji is eligible to receive upfront, development and commercial milestones and royalty payments from the Company. Fortress expects to leverage data from three completed Phase III clinical trials in more than 500 Japanese patients to develop and market Dotinurad.
• In August 2021, Arthrosi Therapeutics announced a joint venture in Guangzhou China with Ruiao Biopharmaceutical Technology Co., Ltd. to form Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd. The joint venture will be responsible for the development of AR882 in the greater China area (Mainland China, Hong Kong, Macao, and Taiwan) while Arthrosi Therapeutics, Inc. continues to lead the global development of AR882 in the gout and tophaceous gout population. In addition, the joint venture will allow Arthrosi to enter the precision medicine oncology therapeutic area by moving AR035, a potent EGFR exon 20 inhibitor targeting non-small cell lung cancer, into the IND-enabling stage.

 

Request for Sample to know more about the therapies that are set to grab maximum patient pool @ https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight

 

Gout is a chronic disease that is caused due to excess accumulation of uric acid in the body, a condition referred to as hyperuricemia. It is a painful and crystal-induced form of arthritis in which crystals of monosodium urate (MSU) precipitate and deposit in joints of lower limbs. Gout is treatable with medications and changes in diet and lifestyle.

 

Gout Pipeline Drugs 

Drug	Company	Phase	MoA	RoA
SEL-212	Selecta Biosciences	Phase III	Urate oxidase replacements	Intravenous
SHR4640	Jiangsu Hengrui Medicine Co.	Phase III	SLC22A12 protein inhibitors	Oral
LC350189	LG Chem	Phase II	Xanthine oxidase inhibitors	Oral
URC-102	JW Pharmaceutical	Phase II	SLC22A12 protein inhibitors	Oral
Dapansutrile	Olatec Therapeutics	Phase II	Inflammasome inhibitors; Interleukin inhibitors; NLRP3 protein inhibitors	Oral
TMX-049	Teijin Pharma	Phase II	Xanthine oxidase inhibitors	NA
SAP-001	Shanton Pharma	Phase II	Urate transporter inhibitors	Oral
XNW3009	Sinovent	Phase I	SLC22A12 protein inhibitors	Oral
PRX-115	Protalix BioTherapeutics	Preclinical	Urate oxidase replacements	Intravenous
NC-2700	Nippon Chemiphar	Preclinical	SLC22A12 protein inhibitors	NA
HZN-003	Horizon Therapeutics	Preclinical	Enzyme replacements	Subcutaneous

 

Request for Sample to know more @ https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight

 

Gout Therapeutic Assessment

The Gout Pipeline report lays down complete insights into active Gout pipeline therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

 

Scope of the Report

Coverage: Global Key Players: Protalix BioTherapeutics, Shanton Pharma, Horizon Therapeutics, JW Pharmaceutical, Jiangsu Hengrui Medicine Co., Nippon Chemiphar, Sinovent, LG Chem, Selecta Biosciences, TWi Biotechnology, Olatec Therapeutics, Hinova pharmaceuticals, Dyve Biosciences, InventisBio, Arrowhead Pharmaceuticals, Wellstat Therapeutics Corporation, Acquist Therapeutics, TaiwanJ Pharmaceuticals, Atom Bioscience

Key Gout Pipeline Therapies: PRX-115, SAP-001, HZN-003, URC-102, SHR4640, NC-2700, XNW3009, LC350189, SEL-212, AC-201, Dapansutrile, HP501, DYV700, D-0120, ARO-XDH, WT-2107, ACQT1127, TJC0434, ABP-072, and many others.

 

Reach out @ https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight

 

Table of Contents 

1	Report Introduction
2	Gout Disease Overview
3	Gout Pipeline Outlook
4	Comparative Analysis
5	Gout Therapeutic Products in Clinical Stage
6	Gout Late Stage Products (Phase III)
6.1	SEL-212: Selecta Biosciences
6.2	SHR4640: Jiangsu Hengrui Medicine Co.
7	Gout Mid Stage Products (Phase II)
7.1	LC350189: LG Chem
7.2	URC-102: JW Pharmaceutical
7.3	SAP-001: Shanton Pharma
8	Gout Early Stage Products (Phase I)
8.1	XNW3009: Sinovent
9	Gout Therapeutic Products in Non-clinical Stage
10	Gout Preclinical and Discovery Stage Products
10.1	HZN-003: Horizon Therapeutics
10.2	PRX-115: Protalix BioTherapeutics
11	Gout Therapeutics Pipeline Analysis
12	Inactive Gout Pipeline Products
13	Appendix
14	Report Methodology
15	Consulting Services
16	Disclaimer
17	About DelveInsight

 

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight